These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 12474122)

  • 1. The CRF(1) receptor antagonist DMP696 produces anxiolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats.
    McElroy JF; Ward KA; Zeller KL; Jones KW; Gilligan PJ; He L; Lelas S
    Psychopharmacology (Berl); 2002 Dec; 165(1):86-92. PubMed ID: 12474122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats.
    Lelas S; Wong H; Li YW; Heman KL; Ward KA; Zeller KL; Sieracki KK; Polino JL; Godonis HE; Ren SX; Yan XX; Arneric SP; Robertson DW; Hartig PR; Grossman S; Trainor GL; Taub RA; Zaczek R; Gilligan PJ; McElroy JF
    J Pharmacol Exp Ther; 2004 Apr; 309(1):293-302. PubMed ID: 14742750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anxiolytic CRF(1) antagonist DMP696 fails to function as a discriminative stimulus and does not substitute for chlordiazepoxide in rats.
    Lelas S; Zeller KL; Ward KA; McElroy JF
    Psychopharmacology (Berl); 2003 Apr; 166(4):408-15. PubMed ID: 12590355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor occupancy of nonpeptide corticotropin-releasing factor 1 antagonist DMP696: correlation with drug exposure and anxiolytic efficacy.
    Li YW; Hill G; Wong H; Kelly N; Ward K; Pierdomenico M; Ren S; Gilligan P; Grossman S; Trainor G; Taub R; McElroy J; Zazcek R
    J Pharmacol Exp Ther; 2003 Apr; 305(1):86-96. PubMed ID: 12649356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacology of DMP696 and DMP904, non-peptidergic CRF1 receptor antagonists.
    Li YW; Fitzgerald L; Wong H; Lelas S; Zhang G; Lindner MD; Wallace T; McElroy J; Lodge NJ; Gilligan P; Zaczek R
    CNS Drug Rev; 2005; 11(1):21-52. PubMed ID: 15867951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a benzodiazepine receptor agonist and corticotropin-releasing hormone receptor antagonists on long-term foot-shock-induced increase in defensive withdrawal behavior.
    Bruijnzeel AW; Stam R; Wiegant VM
    Psychopharmacology (Berl); 2001 Nov; 158(2):132-9. PubMed ID: 11702086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the rat.
    Arborelius L; Skelton KH; Thrivikraman KV; Plotsky PM; Schulz DW; Owens MJ
    J Pharmacol Exp Ther; 2000 Aug; 294(2):588-97. PubMed ID: 10900236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a non-peptide CRF antagonist (DMP696) on the behavioral and endocrine sequelae of maternal separation.
    Maciag CM; Dent G; Gilligan P; He L; Dowling K; Ko T; Levine S; Smith MA
    Neuropsychopharmacology; 2002 May; 26(5):574-82. PubMed ID: 11927182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The involvement of central noradrenergic systems and corticotropin-releasing factor in defensive-withdrawal behavior in rats.
    Yang XM; Gorman AL; Dunn AJ
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1064-70. PubMed ID: 2262892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist.
    Heinrichs SC; De Souza EB; Schulteis G; Lapsansky JL; Grigoriadis DE
    Neuropsychopharmacology; 2002 Aug; 27(2):194-202. PubMed ID: 12093593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists.
    Gilligan PJ; He L; Clarke T; Tivitmahaisoon P; Lelas S; Li YW; Heman K; Fitzgerald L; Miller K; Zhang G; Marshall A; Krause C; McElroy J; Ward K; Shen H; Wong H; Grossman S; Nemeth G; Zaczek R; Arneric SP; Hartig P; Robertson DW; Trainor G
    J Med Chem; 2009 May; 52(9):3073-83. PubMed ID: 19361210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracerebroventricular administration of corticotrophin-releasing hormone receptor antagonists produces different effects on hypothalamic pituitary adrenal responses to novel restraint depending on the stress history of the animal.
    Vining C; Iyer V; Bhatnagar S
    J Neuroendocrinol; 2007 Mar; 19(3):198-207. PubMed ID: 17280593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of chlordiazepoxide on footshock- and corticotropin-releasing factor-induced increases in cortical and hypothalamic norepinephrine secretion in rats.
    Swiergiel AH; Li Y; Wei ZY; Dunn AJ
    Neurochem Int; 2008 May; 52(6):1220-5. PubMed ID: 18280616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the anxiolytic-like effect of TRH and the response of amygdalar TRHergic neurons in anxiety.
    Gutiérrez-Mariscal M; de Gortari P; López-Rubalcava C; Martínez A; Joseph-Bravo P
    Psychoneuroendocrinology; 2008 Feb; 33(2):198-213. PubMed ID: 18079066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential activation of CRF receptor subtypes removes stress-induced memory deficit and anxiety.
    Todorovic C; Radulovic J; Jahn O; Radulovic M; Sherrin T; Hippel C; Spiess J
    Eur J Neurosci; 2007 Jun; 25(11):3385-97. PubMed ID: 17553007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.
    Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Nakazato A; Kumagai T; Okubo T; Tomisawa K
    J Pharmacol Exp Ther; 1999 May; 289(2):926-35. PubMed ID: 10215672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal by quercetin of corticotrophin releasing factor induced anxiety- and depression-like effect in mice.
    Bhutada P; Mundhada Y; Bansod K; Ubgade A; Quazi M; Umathe S; Mundhada D
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):955-60. PubMed ID: 20447436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The behavioural and electrophysiological effects of CRF in rat frontal cortex.
    Zieba B; Grzegorzewska M; Brański P; Domin H; Wierońska JM; Hess G; Smiałowska M
    Neuropeptides; 2008; 42(5-6):513-23. PubMed ID: 18617263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous i.c.v. infusion of brain-derived neurotrophic factor modifies hypothalamic-pituitary-adrenal axis activity, locomotor activity and body temperature rhythms in adult male rats.
    Naert G; Ixart G; Tapia-Arancibia L; Givalois L
    Neuroscience; 2006 May; 139(2):779-89. PubMed ID: 16457953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corticotropin-releasing hormone receptor 1 antagonist blocks brain-gut activation induced by colonic distention in rats.
    Saito K; Kasai T; Nagura Y; Ito H; Kanazawa M; Fukudo S
    Gastroenterology; 2005 Nov; 129(5):1533-43. PubMed ID: 16285953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.